These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 31375912

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
    Woo JW, Lee K, Chung YR, Jang MH, Ahn S, Park SY.
    Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization.
    Bethune GC, Veldhuijzen van Zanten D, MacIntosh RF, Rayson D, Younis T, Thompson K, Barnes PJ.
    Histopathology; 2015 Dec; 67(6):880-7. PubMed ID: 25913507
    [Abstract] [Full Text] [Related]

  • 6. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K, Tantravahi U, Lomme MM, Pasquariello T, Steinhoff M, Sung CJ.
    Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer.
    Xu B, Shen J, Guo W, Zhao W, Zhuang Y, Wang L.
    Pathol Res Pract; 2019 Feb; 215(2):251-255. PubMed ID: 30420102
    [Abstract] [Full Text] [Related]

  • 11. Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results.
    Wang B, Ding W, Sun K, Wang X, Xu L, Teng X.
    Sci Rep; 2019 Nov 13; 9(1):16726. PubMed ID: 31723206
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
    Fan YS, Casas CE, Peng J, Watkins M, Fan L, Chapman J, Ikpatt OF, Gomez C, Zhao W, Reis IM.
    Breast Cancer Res Treat; 2016 Feb 13; 155(3):457-62. PubMed ID: 26895325
    [Abstract] [Full Text] [Related]

  • 14. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.
    Shah SS, Ketterling RP, Goetz MP, Ingle JN, Reynolds CA, Perez EA, Chen B.
    Hum Pathol; 2010 Jan 13; 41(1):103-6. PubMed ID: 19762065
    [Abstract] [Full Text] [Related]

  • 15. Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer.
    Guo L, Yuan P, Zhang J, Ling Y, Li W, Zhao B, Ying J, Xuan L.
    Breast Cancer Res Treat; 2017 Nov 13; 166(1):77-84. PubMed ID: 28712009
    [Abstract] [Full Text] [Related]

  • 16. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
    Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M.
    Arch Pathol Lab Med; 2018 Nov 13; 142(11):1364-1382. PubMed ID: 29846104
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
    Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical Oncology, College of American Pathologists.
    J Clin Oncol; 2013 Nov 01; 31(31):3997-4013. PubMed ID: 24101045
    [Abstract] [Full Text] [Related]

  • 19. Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With HER2/CEP17 Ratio <2.0 and Average HER2 Copy Number ≥4.0 and <6.0.
    Hoda RS, Brogi E, Xu J, Ventura K, Ross DS, Dang C, Robson M, Norton L, Morrow M, Wen HY.
    Arch Pathol Lab Med; 2020 May 01; 144(5):597-601. PubMed ID: 31647316
    [Abstract] [Full Text] [Related]

  • 20. [Impact of 2013 American Society of Clinical Oncology/College of American Pathologist guidelines on borderline immunostaining results for HER2: a retrospective study on HER2 FISH results in 1 780 cases of invasive breast cancers].
    Xu Y, Bai QM, Yang F, Zhu XL, Lu YM, Zhang J, Yang WT, Zhou XY.
    Zhonghua Bing Li Xue Za Zhi; 2016 Aug 08; 45(8):545-9. PubMed ID: 27510780
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.